Skip to content

Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis

Intra-pocket Application of Tea Tree Oil Gel in the Treatment of Stage-2 Periodontitis (A Clinical and Biochemical Study)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04769271
Enrollment
30
Registered
2021-02-24
Start date
2019-11-10
Completion date
2020-08-25
Last updated
2021-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Brief summary

This study aimed to assess clinically and biochemically the effect of intrapocket application of tea tree oil (TTO) gel adjunctive to SRP in the management of stage 2(moderate) periodontitis and to correlate the biochemical levels with clinical response.

Detailed description

A randomized, controlled clinical trial included thirty patients with stage 2 periodontitis. They were equally divided into two groups: Group 1 (control group) treated with scaling and root planning (SRP) alone and Group 2 (test group) managed by SRP and locally delivered 5% tea tree oil (TTO) gel.

Interventions

PROCEDUREScaling and Root Planing

Supra- and sub-gingival calculus and debris were removed

DRUGScaling and Root Planing with tea tree oil

Supra- and sub-gingival calculus and debris were removed and 5% tea tree oil was applied

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with stage 2,grade B periodontitis according to the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. * Patients with CAL 3-4 mm , BOP and radiographic horizontal bone loss related to the coronal third of the root (15%-33%). * Patients with no teeth loss due to periodontitis. * Patients with radiographic bone loss/age % of 0.25-1 %. * Patients who could maintain an O'Leary plaque index ≤10 proceeded into the study.

Exclusion criteria

* Patients with CAL caused by non periodontal causes. * Patients with grade C periodontitis. * Patients having any systemic disease that may affect the treatment outcomes * Smokers. * Pregnant females. * Patients receiving contraindicated medications, chemotherapy, or radiotherapy in the previous year.

Design outcomes

Primary

MeasureTime frameDescription
Probing depthup to 6 monthsProbing depth was recorded at tested sites with graduated William's probe graduated in 1 mm increment. Readings were rounded to the nearest mm.
Clinical attachment lossup to 6 monthsClinical attachment loss was recorded at tested sites with graduated William's probe graduated in 1 mm increment. Readings were rounded to the nearest mm.
Bleeding on probingup to 6 monthsBleeding on probing was assessed at tested sites with graduated William's probe graduated in 1 mm increment, within 15 seconds after probing, using a dichotomous scoring system (+ and -) for presence or absence, respectively.
Biochemical assessment of inlammationup to 6 monthsThis involved determination of the gingival crevicular fluid (GCF) levels of matrix metalloproteinase 8 (MPP-8). A GCF sample was taken from the area showing the deepest pocket depth around the treated area.The samples were diluted in phosphate buffer saline (PBS) up to 1 mL. After waiting for 15 min, the paper points were removed, and 500 μL were centrifuged at 400 g for 4 min, then frozen at -20°C pending MMP-8 analysis using Human Matrix metalloproteinase 8/Neutrophil collagenase (MMP-8) ELISA Kit according to the manufacturer instructions.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026